Subtopic Deep Dive
Radiation-Associated Angiosarcoma
Research Guide
What is Radiation-Associated Angiosarcoma?
Radiation-associated angiosarcoma is a rare, aggressive vascular malignancy arising in previously irradiated tissue, most commonly in breast cancer survivors post-radiotherapy.
This iatrogenic sarcoma typically manifests 5-10 years after radiation exposure with latency periods documented in case series. Maddox and Evans (1981) identified 5 postradiation cases among 44 angiosarcomas at M.D. Anderson, highlighting its distinction from primary forms. Incidence patterns from Toro et al. (2006) analysis of 26,758 soft tissue sarcomas confirm elevated risk post-radiation (661 citations).
Why It Matters
Radiation-associated angiosarcoma impacts radiation therapy protocols for breast cancer, affecting millions of survivors annually. Maddox and Evans (1981) reported poor prognosis in postradiation cases, informing surveillance guidelines in NCCN by von Mehren et al. (2022, 1099 citations) and von Mehren et al. (2018, 720 citations). Surgical resection outcomes guide follow-up imaging, reducing secondary malignancy morbidity as per UK guidelines by Dangoor et al. (2016, 475 citations). Paclitaxel efficacy from Penel et al. ANGIOTAX trial (2008, 680 citations) shapes chemotherapy for unresectable cases.
Key Research Challenges
Long Latency Diagnosis
Detection lags 5-10 years post-radiotherapy, complicating attribution to radiation. Maddox and Evans (1981) noted postradiation cases mimicking lymphedema. Toro et al. (2006) SEER analysis shows underreporting of etiology-specific incidence.
Molecular Pathogenesis Unknown
Radiation-induced genomic instability drives vasculogenesis, but drivers remain unclear. von Mehren et al. (2022) NCCN guidelines call for molecular profiling. No targeted therapies identified in Penel et al. (2008) trial cohort.
Optimal Surveillance Protocols
No standardized imaging or biopsy timing post-radiotherapy exists. Dangoor et al. (2016) UK guidelines recommend vigilant follow-up without specifics. von Mehren et al. (2018) highlight need for prospective studies.
Essential Papers
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.1K citations
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin et al. · 2018 · Journal of the National Comprehensive Cancer Network · 720 citations
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · 2008 · Journal of Clinical Oncology · 680 citations
Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods Thirty pati...
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases
Jorge R. Toro, Lois B. Travis, Hongyu Wu et al. · 2006 · International Journal of Cancer · 661 citations
Abstract Soft tissue sarcomas (STS) are a heterogeneous group of uncommon tumors that show a broad range of differentiation that may reflect etiologic distinction. Routine tabulations of STS are no...
Angiosarcoma of the face and scalp, prognosis and treatment
Colin A. Holden, Margaret F Spittle, Edward Wilson Jones · 1987 · Cancer · 542 citations
72 patients with angiosarcoma (AS) of the face and scalp have been analyzed with respect of various prognostic factors and the effects of different treatment regimes. This disease predominantly occ...
Angiosarcoma of skin and soft tissue: A study of forty-four cases
John C. Maddox, Harry L. Evans · 1981 · Cancer · 542 citations
Forty-four cases of skin and soft tissue angiosarcoma seen at M. D. Anderson Hospital before 1976 were reviewed. The cases fell into six different clinical groups: scalp-face, 17 cases; postmastect...
Primary sarcomas of the heart
Allen Burke, David N. Cowan, Renu Virmani · 1992 · Cancer · 530 citations
Seventy-five primary sarcomas of the heart were classified by histologic appearance as angiosarcoma (26 cases), undifferentiated sarcoma (18 cases), osteosarcoma (9 cases), fibrosarcoma (6 cases), ...
Reading Guide
Foundational Papers
Start with Maddox and Evans (1981, 542 citations) for clinical classification of postradiation cases; Toro et al. (2006, 661 citations) for SEER epidemiology; Penel et al. (2008, 680 citations) for paclitaxel efficacy benchmark.
Recent Advances
von Mehren et al. (2022 NCCN, 1099 citations) for updated guidelines; von Mehren et al. (2018 NCCN, 720 citations) for prior version comparison; Dangoor et al. (2016 UK guidelines, 475 citations) for management consensus.
Core Methods
Histopathology for diagnosis (Maddox-Evans); SEER epidemiology (Toro); phase II trials with weekly paclitaxel 80mg/m² (Penel ANGIOTAX); NCCN risk stratification and surveillance.
How PapersFlow Helps You Research Radiation-Associated Angiosarcoma
Discover & Search
Research Agent uses searchPapers and citationGraph to map radiation-associated angiosarcoma literature from Maddox and Evans (1981), tracing 542 citations to von Mehren et al. (2022) NCCN updates; exaSearch uncovers etiology-specific SEER data from Toro et al. (2006); findSimilarPapers links to Penel et al. ANGIOTAX (2008).
Analyze & Verify
Analysis Agent employs readPaperContent on Maddox and Evans (1981) to extract postradiation case details, verifyResponse with CoVe chain-of-verification cross-checks latency claims against Toro et al. (2006), and runPythonAnalysis performs survival statistics on SEER incidence data; GRADE grading scores NCCN guideline evidence from von Mehren et al. (2022).
Synthesize & Write
Synthesis Agent detects gaps in molecular profiling via contradiction flagging across von Mehren NCCN papers (2018, 2022); Writing Agent uses latexEditText and latexSyncCitations to draft review sections citing Penel et al. (2008), latexCompile for publication-ready output, exportMermaid for latency period timelines.
Use Cases
"Extract incidence rates of radiation-associated angiosarcoma from SEER data and run survival statistics."
Research Agent → searchPapers(Toro 2006) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas on incidence tables) → matplotlib survival curves output.
"Draft LaTeX review on paclitaxel for post-radiation angiosarcoma with NCCN citations."
Synthesis Agent → gap detection(Penel 2008, von Mehren 2022) → Writing Agent → latexEditText(draft section) → latexSyncCitations → latexCompile → PDF with figures.
"Find GitHub repos analyzing radiation-induced sarcoma genomics from cited papers."
Research Agent → paperExtractUrls(von Mehren 2022) → paperFindGithubRepo → Code Discovery → githubRepoInspect → shared code for MYC amplification analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers from citationGraph of Maddox and Evans (1981), generating structured report on latency and outcomes. DeepScan applies 7-step analysis with CoVe checkpoints to verify Penel et al. (2008) paclitaxel response rates against von Mehren NCCN (2022). Theorizer generates hypotheses on radiation-induced TP53 mutations from Toro et al. (2006) incidence patterns.
Frequently Asked Questions
What defines radiation-associated angiosarcoma?
Aggressive vascular tumor arising 5-10 years post-radiotherapy, distinct from primary angiosarcoma; Maddox and Evans (1981) classified 5 cases post-radiation among 44 total.
What are key treatment methods?
Weekly paclitaxel per ANGIOTAX trial (Penel et al., 2008, 30 patients, response rate 62%); surgical resection primary, per NCCN von Mehren et al. (2022).
What are seminal papers?
Maddox and Evans (1981, 542 citations, postradiation cases); Toro et al. (2006, 661 citations, SEER incidence); Penel et al. (2008, 680 citations, paclitaxel trial).
What open problems persist?
Molecular drivers unknown; surveillance protocols unstandardized (von Mehren et al. 2022); prospective latency studies needed (Dangoor et al. 2016).
Research Vascular Tumors and Angiosarcomas with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Radiation-Associated Angiosarcoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Tumors and Angiosarcomas Research Guide